

Genomic evidence for reinfection with SARS-CoV-2: a c

Lancet Infectious Diseases, The
21, 52-58

DOI: [10.1016/s1473-3099\(20\)30764-7](https://doi.org/10.1016/s1473-3099(20)30764-7)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Understanding protection from SARS-CoV-2 by studying reinfection. <i>Nature Medicine</i> , 2020, 26, 1680-1681.	15.2	44
2	Antibody Responses to SARS-CoV-2 Antigens in Humans and Animals. <i>Vaccines</i> , 2020, 8, 684.	2.1	11
3	The immunology of SARS-CoV-2 infections and vaccines. <i>Seminars in Immunology</i> , 2020, 50, 101422.	2.7	85
4	Can we pursue a "herd immunity" policy?. <i>Infection Control and Hospital Epidemiology</i> , 2020, , 1-2.	1.0	0
5	No Evidence of Re-infection or Person-to-Person Transmission in Cured COVID-19 Patients in Guangzhou, a Retrospective Observational Study. <i>Frontiers in Medicine</i> , 2020, 7, 593133.	1.2	3
6	Risks of Aerosol Contamination in Dental Procedures during the Second Wave of COVID-19: Experience and Proposals of Innovative IPC in Dental Practice. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 8954.	1.2	26
7	SARS-CoV-2 Vaccines: Inactivation by Gamma Irradiation for T and B Cell Immunity. <i>Pathogens</i> , 2020, 9, 928.	1.2	3
8	Emerging antibody-based therapeutics against SARS-CoV-2 during the global pandemic. <i>Antibody Therapeutics</i> , 2020, 3, 246-256.	1.2	34
9	Will SARS-CoV-2 Infection Elicit Long-Lasting Protective or Sterilising Immunity? Implications for Vaccine Strategies (2020). <i>Frontiers in Immunology</i> , 2020, 11, 571481.	2.2	48
10	Persistent Detection and Infectious Potential of SARS-CoV-2 Virus in Clinical Specimens from COVID-19 Patients. <i>Viruses</i> , 2020, 12, 1384.	1.5	46
12	What reinfections mean for COVID-19. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 3-5.	4.6	201
13	Over 90% of clinical swabs used for SARS-CoV-2 diagnostics contain sufficient nucleic acid concentrations. <i>Journal of Medical Virology</i> , 2021, 93, 2848-2856.	2.5	4
14	One year update on the COVID-19 pandemic: Where are we now?. <i>Acta Tropica</i> , 2021, 214, 105778.	0.9	142
15	Definitions for coronavirus disease 2019 reinfection, relapse and PCR re-positivity. <i>Clinical Microbiology and Infection</i> , 2021, 27, 315-318.	2.8	141
16	Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assay. <i>Journal of Virological Methods</i> , 2021, 288, 114025.	1.0	94
17	COVID-19 Antibody Tests: A Valuable Public Health Tool with Limited Relevance to Individuals. <i>Trends in Microbiology</i> , 2021, 29, 214-223.	3.5	73
18	A case of SARS-CoV-2 reinfection in Ecuador. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e142.	4.6	72
19	Antibodies, Immunity, and COVID-19. <i>JAMA Internal Medicine</i> , 2021, 181, 460.	2.6	34

#	ARTICLE	IF	CITATIONS
20	Recurrent COVID-19 pneumonia in the course of chemotherapy: Consequence of a weakened immune system?. <i>Journal of Medical Virology</i> , 2021, 93, 1882-1884.	2.5	20
21	Functional importance of the D614G mutation in the SARS-CoV-2 spike protein. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 108-115.	1.0	79
22	Evidence of SARS-CoV-2 re-infection with a different genotype. <i>Journal of Infection</i> , 2021, 82, 84-123.	1.7	47
23	Challenges in Testing for SARS-CoV-2 Among Patients Who Recovered From COVID-19. <i>JAMA Internal Medicine</i> , 2021, 181, 704.	2.6	5
24	Blockchain technologies to mitigate COVID-19 challenges: A scoping review. <i>Computer Methods and Programs in Biomedicine Update</i> , 2021, 1, 100001.	2.3	42
25	Rates of recurrent positive SARS-CoV-2 swab results among patients attending primary care in Qatar. <i>Journal of Infection</i> , 2021, 82, 84-123.	1.7	5
26	Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. <i>New England Journal of Medicine</i> , 2021, 384, 533-540.	13.9	803
27	The scientific and ethical feasibility of immunity passports. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e58-e63.	4.6	82
28	Blood Biomarkers for Detection of Brain Injury in COVID-19 Patients. <i>Journal of Neurotrauma</i> , 2021, 38, 1-43.	1.7	68
29	Pathogenesis guided therapeutic management of COVID-19: an immunological perspective. <i>International Reviews of Immunology</i> , 2021, 40, 54-71.	1.5	10
30	Immunity Passports and Entrepreneurial Opportunities in the COVID-19 Era. <i>Springer Proceedings in Business and Economics</i> , 2021, , 187-198.	0.3	0
31	A fractional complex network model for novel corona virus in China. <i>Advances in Difference Equations</i> , 2021, 2021, 5.	3.5	4
32	Modeling of the COVID-19 pandemic in the limit of no acquired immunity. <i>Mathematical Modeling and Computing</i> , 2021, 8, 282-303.	0.4	5
33	COVID Re-Infection or Something Else? A Case Report. <i>Journal of Scientific Innovation in Medicine</i> , 2021, 4, .	0.1	0
34	Constructing an ethical framework for priority allocation of pandemic vaccines. <i>Vaccine</i> , 2021, 39, 797-804.	1.7	9
35	Stem cells part of the innate and adaptive immune systems as a therapeutic for Covid-19. <i>Communicative and Integrative Biology</i> , 2021, 14, 186-198.	0.6	6
36	A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques. <i>Emerging Microbes and Infections</i> , 2021, 10, 342-355.	3.0	37
37	Case Reports of COVID 19 Recurrence. <i>Journal of Primary Care and Community Health</i> , 2021, 12, 215013272098275.	1.0	10

#	ARTICLE	IF	CITATIONS
38	The role and uses of antibodies in COVID-19 infections: a living review. Oxford Open Immunology, 2021, 2, iqab003.	1.2	17
39	Laboratory-confirmed SARS-CoV-2 reinfection in the population treated at social security. Respiratory Medicine Case Reports, 2021, 34, 101493.	0.2	4
40	A systematic review on the recurrence of SARS-CoV-2 virus: frequency, risk factors, and possible explanations. Infectious Diseases, 2021, 53, 315-324.	1.4	29
41	How strong is the evidence that it is possible to get SARS-CoV-2 twice? A systematic review. Reviews in Medical Virology, 2021, 31, 1-12.	3.9	7
42	Decline in neutralising antibody responses, but sustained T-cell immunity, in COVID-19 patients at 7 months post-infection. Clinical and Translational Immunology, 2021, 10, e1319.	1.7	34
43	Prior SARS-CoV-2 Infection Prevents Acute Disease and Lung Pathology in Reinfected Syrian Hamsters but not Virus Replication in the Upper Respiratory Tract. SSRN Electronic Journal, 0, , .	0.4	3
44	A first probable case of SARS-CoV-2 reinfection in Colombia. Annals of Clinical Microbiology and Antimicrobials, 2021, 20, 7.	1.7	12
45	Possible COVID-19 reinfection case in Duhok City, Kurdistan: A case report. Journal of Family Medicine and Primary Care, 2021, 10, 2035.	0.3	5
46	How can we interpret SARS-CoV-2 antibody test results?. Pathogens and Disease, 2021, 79, .	0.8	15
48	Evidence for immunity to SARS-CoV-2 from epidemiological data series. F1000Research, 0, 10, 50.	0.8	0
49	Symptomatic recurrence of SARS-CoV-2 infection in healthcare workers recovered from COVID-19. Journal of Infection in Developing Countries, 2021, 15, 69-72.	0.5	7
50	COVID-19 re-infection or persistent infection in patient with acute myeloid leukaemia M3: a mini review. New Microbes and New Infections, 2021, 39, 100830.	0.8	7
51	Backward transmission of COVID-19 from humans to animals may propagate reinfections and induce vaccine failure. Environmental Chemistry Letters, 2021, 19, 763-768.	8.3	42
52	Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies. Vaccines, 2021, 9, 99.	2.1	24
53	Cardiovascular Disease and Coronavirus Disease 2019: Epidemiology, Management, and Prevention. Current Epidemiology Reports, 2021, 8, 1-8.	1.1	12
54	Towards Bayesian Evaluation of Seroprevalence Studies. Medical Sciences Forum, 2021, 4, .	0.5	0
55	SARS-CoV-2 and approaches for a testing and diagnostic strategy. Journal of Materials Chemistry B, 2021, 9, 8157-8173.	2.9	4
56	Clinical characteristics of re-hospitalized COVID-19 patients with recurrent positive SARS-CoV-2 RNA: a retrospective study. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 1245-1252.	1.3	8

#	ARTICLE	IF	CITATIONS
57	COVID-19 re-infection in Shahroud, Iran: a follow-up study. <i>Epidemiology and Infection</i> , 2021, 149, e159.	1.0	16
58	Do Antibody Positive Healthcare Workers Have Lower SARS-CoV-2 Infection Rates than Antibody Negative Healthcare Workers? Large Multi-Centre Prospective Cohort Study (The SIREN Study), England: June to November 2020. <i>SSRN Electronic Journal</i> , 0, , .	0.4	7
59	The evolutionary dynamics of endemic human coronaviruses. <i>Virus Evolution</i> , 2021, 7, veab020.	2.2	40
60	Confirmed Reinfection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant VOC-202012/01. <i>Clinical Infectious Diseases</i> , 2021, 73, 1946-1947.	2.9	85
61	SARS-CoV-2 pandemic-induced PPE and single-use plastic waste generation scenario. <i>Waste Management and Research</i> , 2021, 39, 3-17.	2.2	51
62	Heterogeneous magnitude of immunological memory to SARS-CoV-2 in recovered individuals. <i>Clinical and Translational Immunology</i> , 2021, 10, e1281.	1.7	19
63	The 2020 race towards SARS-CoV-2 specific vaccines. <i>Theranostics</i> , 2021, 11, 1690-1702.	4.6	71
65	Specific epitopes form extensive hydrogen-bonding networks to ensure efficient antibody binding of SARS-CoV-2: Implications for advanced antibody design. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 1661-1671.	1.9	7
66	Prior aerosol infection with lineage A SARS-CoV-2 variant protects hamsters from disease, but not reinfection with B.1.351 SARS-CoV-2 variant. <i>Emerging Microbes and Infections</i> , 2021, 10, 1284-1292.	3.0	25
68	Lies, Gosh Darn Lies, and not enough good statistics: why epidemic model parameter estimation fails. <i>Scientific Reports</i> , 2021, 11, 408.	1.6	1
69	SISDH: A Model Based on SMAs and SIRs for the Simulation of the Evolution of COVID-19 in Cameroon. <i>World Journal of Engineering and Technology</i> , 2021, 09, 527-537.	0.3	0
70	SARS-CoV-2 re-infection: development of an epidemiological definition from India. <i>Epidemiology and Infection</i> , 2021, 149, e82.	1.0	33
71	COVID-19 reinfection in the presence of neutralizing antibodies. <i>National Science Review</i> , 2021, 8, nwab006.	4.6	24
72	Experimental re-infected cats do not transmit SARS-CoV-2. <i>Emerging Microbes and Infections</i> , 2021, 10, 638-650.	3.0	48
73	Understanding the implications of SARS-CoV-2 re-infections on immune response milieu, laboratory tests and control measures against COVID-19. <i>Heliyon</i> , 2021, 7, e05951.	1.4	15
75	Stereotypic neutralizing V _H antibodies against SARS-CoV-2 spike protein receptor binding domain in patients with COVID-19 and healthy individuals. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	72
77	Exploring COVID-19: Relating the spike protein to infectivity, pathogenicity and Immunogenicity. <i>International Journal of Clinical Virology</i> , 2021, 5, 001-010.	0.1	2
79	Dynamics of a Dual SARS-CoV-2 Lineage Co-Infection on a Prolonged Viral Shedding COVID-19 Case: Insights into Clinical Severity and Disease Duration. <i>Microorganisms</i> , 2021, 9, 300.	1.6	48

#	ARTICLE	IF	CITATIONS
80	Reinfection versus failure of viral clearance in a COVID-19 patient with hematologic malignancy. <i>Leukemia Research</i> , 2021, 101, 106514.	0.4	4
81	Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. <i>Science</i> , 2021, 371, .	6.0	2,268
82	Long-Term Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectiousness Among Three Immunocompromised Patients: From Prolonged Viral Shedding to SARS-CoV-2 Superinfection. <i>Journal of Infectious Diseases</i> , 2021, 223, 1522-1527.	1.9	125
83	COVID-19 and Dentistry in 72 Questions: An Overview of the Literature. <i>Journal of Clinical Medicine</i> , 2021, 10, 779.	1.0	21
84	Sustainable Resumption of Cardiac Catheterization Laboratory Procedures, and the Importance of Testing, During Endemic COVID-19. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2021, 23, 22.	0.4	6
85	Fizzle Testing: An Equation Utilizing Random Surveillance to Help Reduce COVID-19 Risks. <i>Mathematical and Computational Applications</i> , 2021, 26, 16.	0.7	3
86	COVID-19: Current knowledge in clinical features, immunological responses, and vaccine development. <i>FASEB Journal</i> , 2021, 35, e21409.	0.2	71
89	SARS-CoV-2 Immuno-Pathogenesis and Potential for Diverse Vaccines and Therapies: Opportunities and Challenges. <i>Infectious Disease Reports</i> , 2021, 13, 102-125.	1.5	24
90	Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies. <i>Frontiers in Immunology</i> , 2021, 12, 640093.	2.2	93
91	COVID-19 in Autoinflammatory Diseases with Immunosuppressive Treatment. <i>Journal of Clinical Medicine</i> , 2021, 10, 605.	1.0	13
92	Evidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection Without Mutations in the Spike Protein. <i>Clinical Infectious Diseases</i> , 2021, 73, e1239-e1241.	2.9	10
93	Reinfection or Reactivation of Coronavirus-19 in Patients with Hematologic Malignancies: Case Report Series. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 670-674.	0.3	11
94	In silico analysis suggests less effective MHC-II presentation of SARS-CoV-2 RBM peptides: Implication for neutralizing antibody responses. <i>PLoS ONE</i> , 2021, 16, e0246731.	1.1	7
95	Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers. <i>Nature Communications</i> , 2021, 12, 844.	5.8	146
96	COVID-19: Rethinking the Lockdown Groupthink. <i>Frontiers in Public Health</i> , 2021, 9, 625778.	1.3	80
98	Recurrent coronavirus diseases 19 (COVID-19): A different presentation from the first episode. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, 2149-2152.	0.2	6
100	SARS-CoV-2: phylogenetic origins, pathogenesis, modes of transmission, and the potential role of nanotechnology. <i>VirusDisease</i> , 2021, 32, 1-12.	1.0	28
101	Severe Reinfection With South African Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant 501Y.V2. <i>Clinical Infectious Diseases</i> , 2021, 73, 1945-1946.	2.9	77

#	ARTICLE	IF	CITATIONS
103	Effect of thymalin on adaptive immunity in complex therapy for patients with COVID-19. <i>Klinicheskaia Meditsina</i> , 2021, 98, 593-599.	0.2	0
105	A case of SARS-CoV-2 reinfection in a patient with obstructive sleep apnea managed with telemedicine. <i>BMJ Case Reports</i> , 2021, 14, e240496.	0.2	14
106	Current mutasome of SARS-CoV-2 in Turkey reveals mutations of interest. <i>Turkish Journal of Biology</i> , 2021, 45, 104-113.	2.1	8
107	Clinical, Serological, Whole Genome Sequence Analyses to Confirm SARS-CoV-2 Reinfection in Patients From Mumbai, India. <i>Frontiers in Medicine</i> , 2021, 8, 631769.	1.2	21
108	In-Silico Pangenomics of SARS-CoV-2 Isolates Reveal Evidence for Subtle Adaptive Expression Strategies, Continued Clonal Evolution, and Sub-Clonal Emergences, Despite Genome Stability. <i>Microbiology Research</i> , 2021, 12, 204-233.	0.8	4
109	Repeated SARS-CoV-2 Positivity: Analysis of 123 Cases. <i>Viruses</i> , 2021, 13, 512.	1.5	24
110	Cellular and Humoral Immune Responses in Covid-19 and Immunotherapeutic Approaches. <i>ImmunoTargets and Therapy</i> , 2021, Volume 10, 63-85.	2.7	40
111	Familial Clustering and Reinfection With 2019 Novel Coronavirus (COVID-19, SARS-CoV-2) in the Libyan Community. <i>Disaster Medicine and Public Health Preparedness</i> , 2022, 16, 1710-1712.	0.7	3
112	The Impact of Increasing Disease Prevalence, False Omissions, and Diagnostic Uncertainty on Coronavirus Disease 2019 (COVID-19) Test Performance. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 797-813.	1.2	14
113	Repurposing Quinoline and Artemisinin Antimalarials as Therapeutics for SARS-CoV-2: Rationale and Implications. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 613-623.	2.5	9
114	COVID-19: No Guaranteed Protection from Future Infection after the Initial Diagnosis. <i>Case Reports in Infectious Diseases</i> , 2021, 2021, 1-8.	0.2	0
115	Clinical characteristics of SARS-CoV-2 by re-infection vs. reactivation: a case series from Iran. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 1713-1719.	1.3	24
117	Persistent positivity of SARS-CoV-2 nucleic acid in asymptomatic healthcare worker: infective virion or inactive nucleic acid?. <i>BMJ Case Reports</i> , 2021, 14, e241087.	0.2	9
118	Phylogenomic Evidence of Reinfection and Persistence of SARS-CoV-2: First Report from Colombia. <i>Vaccines</i> , 2021, 9, 282.	2.1	14
120	COVID-19 and liver disease: mechanistic and clinical perspectives. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 348-364.	8.2	272
121	The Impact of COVID-19 on Primary Care General Practice Consultations in a Teaching Hospital in Shanghai, China. <i>Frontiers in Medicine</i> , 2021, 8, 642496.	1.2	20
122	A Possible COVID-19 Reinfection Case in a Healthcare Professional. <i>Eurasian Journal of Family Medicine Avrasya Aile HekimliÄyi Dergisi</i> , 2021, 10, 36-40.	0.0	0
123	Recurrent COVID-19 including evidence of reinfection and enhanced severity in thirty Brazilian healthcare workers. <i>Journal of Infection</i> , 2021, 82, 399-406.	1.7	106

#	ARTICLE	IF	CITATIONS
125	Understanding the outcomes of COVID-19 – does the current model of an acute respiratory infection really fit?. <i>Journal of General Virology</i> , 2021, 102, .	1.3	25
126	Identifying Primate ACE2 Variants That Confer Resistance to SARS-CoV-2. <i>Molecular Biology and Evolution</i> , 2021, 38, 2715-2731.	3.5	22
127	The Importance and Challenges of Identifying SARS-CoV-2 Reinfections. <i>Journal of Clinical Microbiology</i> , 2021, 59, .	1.8	73
128	Clinical performance of Roche cobas 6800, Luminex ARIES, MiRXES Fortitude Kit 2.1, Altona RealStar, and Applied Biosystems TaqPath for SARS-CoV-2 detection in nasopharyngeal swabs. <i>Journal of Medical Virology</i> , 2021, 93, 4603-4607.	2.5	13
129	Case Study: Longitudinal immune profiling of a SARS-CoV-2 reinfection in a solid organ transplant recipient. , 2021, , .		3
130	COVID-19 Reinfection in the Face of a Detectable Antibody Titer. <i>Cureus</i> , 2021, 13, e14033.	0.2	4
131	Coronavirus Disease-2019 (COVID-19) and the Liver. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	10
132	Epidemiological Differences in the Impact of COVID-19 Vaccination in the United States and China. <i>Vaccines</i> , 2021, 9, 223.	2.1	20
133	Symptomatic Reinfection in Previously Recovered Coronavirus Disease 2019 (COVID-19) Geriatric Patient. <i>Cureus</i> , 2021, 13, e13961.	0.2	0
134	Impact of reproduction number on the multiwave spreading dynamics of COVID-19 with temporary immunity: A mathematical model. <i>International Journal of Infectious Diseases</i> , 2021, 104, 649-654.	1.5	20
136	COVID-19 vaccines: The status and perspectives in delivery points of view. <i>Advanced Drug Delivery Reviews</i> , 2021, 170, 1-25.	6.6	262
137	Persistence of Anti-SARS-CoV-2 Antibodies Depends on the Analytical Kit: A Report for Up to 10 Months after Infection. <i>Microorganisms</i> , 2021, 9, 556.	1.6	52
138	Reinfection Rates Among Patients Who Previously Tested Positive for Coronavirus Disease 2019: A Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, 1882-1886.	2.9	114
140	A Case Series Describing the Recurrence of COVID-19 in Patients Who Recovered from Initial Illness in Bangladesh. <i>Tropical Medicine and Infectious Disease</i> , 2021, 6, 41.	0.9	9
141	<scp>COVID</scp>-19: immunopathology, pathophysiological mechanisms, and treatment options. <i>Journal of Pathology</i> , 2021, 254, 307-331.	2.1	86
142	COVID-19: One year together. <i>Jurnal Infektologii</i> , 2021, 13, 5-12.	0.1	2
143	Possible COVID-19 reinfection in a patient with X-linked agammaglobulinaemia. <i>BMJ Case Reports</i> , 2021, 14, e240765.	0.2	12
144	Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. <i>Lancet, The</i> , 2021, 397, 1204-1212.	6.3	545

#	ARTICLE	IF	CITATIONS
145	Analysis of IgM, IgA, and IgG isotype antibodies Directed against SARS-CoV-2 spike glycoprotein and ORF8 in the course of COVID-19. <i>Scientific Reports</i> , 2021, 11, 8920.	1.6	15
146	Reinfection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients Undergoing Serial Laboratory Testing. <i>Clinical Infectious Diseases</i> , 2022, 74, 294-300.	2.9	57
147	Comparison of seroprevalence of SARS-CoV-2 infections with cumulative and imputed COVID-19 cases: Systematic review. <i>PLoS ONE</i> , 2021, 16, e0248946.	1.1	71
148	Coronavirus disease 2019 and the revival of passive immunization: Antibody therapy for inhibiting severe acute respiratory syndrome coronavirus 2 and preventing host cell infection: IUPHAR review 31. <i>British Journal of Pharmacology</i> , 2021, 178, 3359-3372.	2.7	10
150	Practicability of serological assays for upscaling COVID-19 laboratory testing in Africa. <i>Journal of Global Health</i> , 2021, 11, 03038.	1.2	0
151	Disparities of SARS-CoV-2 Nucleoprotein-Specific IgG in Healthcare Workers in East London, UK. <i>Frontiers in Medicine</i> , 2021, 8, 642723.	1.2	10
152	Correlates of protection from SARS-CoV-2 infection. <i>Lancet, The</i> , 2021, 397, 1421-1423.	6.3	99
153	What are the Clinical Implications of a Positive RT-PCR Test 6 Months after a Mild SARS-CoV-2 Infection?. <i>European Journal of Case Reports in Internal Medicine</i> , 2021, 8, 002463.	0.2	2
154	Prior COVID-19 significantly reduces the risk of subsequent infection, but reinfections are seen after eight months. <i>Journal of Infection</i> , 2021, 82, e11-e12.	1.7	41
155	An update to monoclonal antibody as therapeutic option against COVID-19. <i>Biosafety and Health</i> , 2021, 3, 87-91.	1.2	97
157	Nature and Duration of Protective Antibodies Developed After COVID-19 Infection. <i>Cocuk Enfeksiyon Dergisi</i> , 2021, 15, 58-61.	0.0	0
158	A systematic review and meta-analysis of discharged COVID-19 patients retesting positive for RT-PCR. <i>EClinicalMedicine</i> , 2021, 34, 100839.	3.2	17
159	Impact of the COVID-19 pandemic â€“ a mental health service perspective. <i>Progress in Neurology and Psychiatry</i> , 2021, 25, 27.	0.4	70
160	Knowledge, Attitudes, Practices and Some Characteristic Features of People Recovered from COVID-19 in Turkey. <i>Medicina (Lithuania)</i> , 2021, 57, 431.	0.8	7
161	SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). <i>Lancet, The</i> , 2021, 397, 1459-1469.	6.3	557
162	SARS-CoV-2 Transmission Risk Among National Basketball Association Players, Staff, and Vendors Exposed to Individuals With Positive Test Results After COVID-19 Recovery During the 2020 Regular and Postseason. <i>JAMA Internal Medicine</i> , 2021, 181, 960-966.	2.6	32
163	SARS-CoV-2 Reinfection in a Healthcare Worker Despite the Presence of Detectable Neutralizing Antibodies. <i>Viruses</i> , 2021, 13, 661.	1.5	27
164	Fulminant hepatic failure in a patient testing re-positive for SARS-CoV-2: a case report. <i>International Journal of Emergency Medicine</i> , 2021, 14, 24.	0.6	5

#	ARTICLE	IF	CITATIONS
165	Immunoglobulin Response and Prognostic Factors in Repeated SARS-CoV-2 Positive Patients: A Systematic Review and Meta-Analysis. <i>Viruses</i> , 2021, 13, 809.	1.5	2
167	Landscape of humoral immune responses against SARS-CoV-2 in patients with COVID-19 disease and the value of antibody testing. <i>Heliyon</i> , 2021, 7, e06836.	1.4	11
168	COVID-19 Reinfection in a Patient Receiving Immunosuppressive Treatment for Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1091-1092.	2.9	9
169	Reinfection or reactivation: Genome-based two distinct SNP profile of SARS-CoV2 repositivity in an Indian case. <i>Journal of Medical Virology</i> , 2021, 93, 4152-4155.	2.5	3
171	Understanding the Challenges and Uncertainties of Seroprevalence Studies for SARS-CoV-2. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 4640.	1.2	25
172	Perspective: diagnostic laboratories should urgently develop T cell assays for SARS-CoV-2 infection. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 421-430.	1.3	24
173	SARS-CoV-2 reinfection in a closed setting: lessons for the community. <i>Lancet Respiratory Medicine</i> , 2021, 9, 675-677.	5.2	3
174	The risk of SARS-CoV-2 reinfection in Duhok city, Kurdistan Region of Iraq. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2021, 13, e2021035.	0.5	8
175	Pandemic analysis of infection and death correlated with genomic open reading frame 10 mutation in severe acute respiratory syndrome coronavirus 2 victims. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 478-484.	0.6	12
176	Reinfection of SARS-CoV-2 – analysis of 23 cases from the literature. <i>Infectious Diseases</i> , 2021, 53, 1-7.	1.4	12
177	Development of Spike Receptor-Binding Domain Nanoparticles as a Vaccine Candidate against SARS-CoV-2 Infection in Ferrets. <i>MBio</i> , 2021, 12, .	1.8	40
178	Antibody Responses in COVID-19: A Review. <i>Frontiers in Immunology</i> , 2021, 12, 633184.	2.2	105
179	Learning from SARS and MERS: COVID-19 reinfection where do we stand?. <i>Travel Medicine and Infectious Disease</i> , 2021, 41, 102024.	1.5	5
180	Reinfection with SARS-CoV-2: A case report from Libya. <i>Travel Medicine and Infectious Disease</i> , 2021, 41, 102040.	1.5	4
181	IgM anti-SARS-CoV-2-specific determination: useful or confusing? Big Data analysis of a real-life scenario. <i>Internal and Emergency Medicine</i> , 2021, 16, 2327-2330.	1.0	8
182	The potential significance of high avidity immunoglobulin G (IgG) for protective immunity towards SARS-CoV-2. <i>International Journal of Infectious Diseases</i> , 2021, 106, 61-64.	1.5	65
184	Clinical, virologic and immunologic features of a mild case of SARS-CoV-2 reinfection. <i>Clinical Microbiology and Infection</i> , 2021, 27, 791.e1-791.e4.	2.8	22
185	SARS-CoV-2 reinfection. <i>Medicina Intensiva (English Edition)</i> , 2021, 45, 375-376.	0.1	1

#	ARTICLE	IF	CITATIONS
186	Zoonotic potential of Newcastle disease virus: Old and novel perspectives related to public health. <i>Reviews in Medical Virology</i> , 2022, 32, .	3.9	19
187	Reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.7 variant in an immunocompromised adolescent. <i>Infection Control and Hospital Epidemiology</i> , 2021, , 1-2.	1.0	6
188	SARS-CoV-2 reinfection: Two cases from Ethiopia. , 0, 2, 114-116.		0
189	Rehabilitation strategies and neurological consequences in patients with COVID-19: part II. <i>Physical Therapy Reviews</i> , 2021, 26, 222-234.	0.3	0
190	Viral dynamics and antibody responses in people with asymptomatic SARS-CoV-2 infection. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 181.	7.1	11
191	Estimating infectiousness throughout SARS-CoV-2 infection course. <i>Science</i> , 2021, 373, .	6.0	389
192	Contribution of Serological Rapid Diagnostic Tests to the Strategy of Contact Tracing in Households Following SARS-CoV-2 Infection Diagnosis in Children. <i>Frontiers in Pediatrics</i> , 2021, 9, 638502.	0.9	4
193	Reinfection by SARS-CoV-2: The first one in a family reported in Spain. <i>Medicina Clínica</i> , 2021, 157, e321-e323.	0.3	4
194	Shedding of infectious SARS-CoV-2 by hospitalized COVID-19 patients in relation to serum antibody responses. <i>BMC Infectious Diseases</i> , 2021, 21, 494.	1.3	16
195	Analysis of the potential impact of durability, timing, and transmission blocking of COVID-19 vaccine on morbidity and mortality. <i>EClinicalMedicine</i> , 2021, 35, 100863.	3.2	35
196	The COVID-19 Menace. <i>Global Challenges</i> , 2021, 5, 2100004.	1.8	5
197	Predicting the dynamical behavior of COVID-19 epidemic and the effect of control strategies. <i>Chaos, Solitons and Fractals</i> , 2021, 146, 110823.	2.5	16
198	Persistence of Antibody and Cellular Immune Responses in Coronavirus Disease 2019 Patients Over Nine Months After Infection. <i>Journal of Infectious Diseases</i> , 2021, 224, 586-594.	1.9	59
199	Post-COVID-19 Syndrome and the Potential Benefits of Exercise. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 5329.	1.2	186
200	SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients. <i>Science Immunology</i> , 2021, 6, .	5.6	455
201	Practical guidance for clinical laboratories for SARS-CoV-2 serology testing. <i>Canada Communicable Disease Report</i> , 2021, 47, 171-183.	0.6	12
202	Relapse of clinical symptoms of COVID-19 or probable reinfection in a laboratory professional: a case report from Northeast Brazil. <i>Research, Society and Development</i> , 2021, 10, e13210514730.	0.0	0
203	Genetics of COVID-19. <i>Journal of Clinical Practice</i> , 2021, 12, 41-52.	0.2	5

#	ARTICLE	IF	CITATIONS
205	Evidence for immunity to SARS-CoV-2 from epidemiological data series. <i>F1000Research</i> , 0, 10, 50.	0.8	0
206	Genetic Evidence and Host Immune Response in Persons Reinfected with SARS-CoV-2, Brazil. <i>Emerging Infectious Diseases</i> , 2021, 27, 1446-1453.	2.0	19
208	The precariousness of political management of the SARS-CoV-2 pandemic in the search for scientific answers: Calling for prudence in public health emergencies. <i>International Journal of Health Planning and Management</i> , 2021, 36, 1387-1391.	0.7	11
209	Containing a pandemic: nonpharmaceutical interventions and the "second wave"™. <i>Journal of Physics Communications</i> , 2021, 5, 055008.	0.5	10
210	SARS-CoV-2 Reinfection among Healthcare Workers in Mexico: Case Report and Literature Review. <i>Medicina (Lithuania)</i> , 2021, 57, 442.	0.8	10
211	Recurrent COVID-19 in Hemodialysis: A Case Report of 2 Possible Reinfections. <i>Kidney Medicine</i> , 2021, 3, 447-450.	1.0	3
212	COVID-2019 fundamentals. <i>Journal of the American Dental Association</i> , 2021, 152, 354-363.	0.7	10
213	Old vaccines for new infections: Exploiting innate immunity to control COVID-19 and prevent future pandemics. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	69
214	COVID-19 contamination among maxillofacial surgeons and impact in Brazilian public center. <i>Journal of Stomatology, Oral and Maxillofacial Surgery</i> , 2022, 123, 92-94.	0.5	1
216	Insights into SARS-CoV-2 Persistence and Its Relevance. <i>Viruses</i> , 2021, 13, 1025.	1.5	37
217	Case series of four re-infections with a SARS-CoV-2 B.1.351 variant, Luxembourg, February 2021. <i>Eurosurveillance</i> , 2021, 26, .	3.9	16
218	Genomic Evidence of SARS-CoV-2 Reinfection Involving E484K Spike Mutation, Brazil. <i>Emerging Infectious Diseases</i> , 2021, 27, 1522-1524.	2.0	181
219	The demography and characteristics of SARS-CoV-2 seropositive residents and staff of nursing homes for older adults in the Community of Madrid: the SeroSOS study. <i>Age and Ageing</i> , 2021, 50, 1038-1047.	0.7	29
220	Platforms for Personalized Polytherapeutics Discovery in COVID-19. <i>Journal of Molecular Biology</i> , 2021, 433, 166945.	2.0	4
221	SARS-CoV-2 infection in general practice in Ireland: a seroprevalence study. <i>BJGP Open</i> , 2021, 5, BJGPO.2021.0038.	0.9	3
222	Evaluation of potential COVID-19 recurrence in patients with late repeat positive SARS-CoV-2 testing. <i>PLoS ONE</i> , 2021, 16, e0251214.	1.1	19
223	Dynamics of SARS-CoV-2 with waning immunity in the UK population. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2021, 376, 20200274.	1.8	31
224	Deconvoluting the T Cell Response to SARS-CoV-2: Specificity Versus Chance and Cognate Cross-Reactivity. <i>Frontiers in Immunology</i> , 2021, 12, 635942.	2.2	20

#	ARTICLE	IF	CITATIONS
225	Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection. <i>JAMA Internal Medicine</i> , 2021, 181, 672.	2.6	236
226	SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. <i>EClinicalMedicine</i> , 2021, 35, 100861.	3.2	153
227	Symptomatic SARS-CoV-2 Reinfection in a Healthy Healthcare Worker in Italy Confirmed by Whole-Genome Sequencing. <i>Viruses</i> , 2021, 13, 899.	1.5	7
228	Potent SARS-CoV-2-Specific T Cell Immunity and Low Anaphylatoxin Levels Correlate With Mild Disease Progression in COVID-19 Patients. <i>Frontiers in Immunology</i> , 2021, 12, 684014.	2.2	37
229	COVID-19: individual and herd immunity. <i>Comptes Rendus - Biologies</i> , 2021, 344, 7-18.	0.1	2
230	Proper Assignment of Reactivation in a COVID-19 Recurrence Initially Interpreted as a Reinfection. <i>Journal of Infectious Diseases</i> , 2021, 224, 788-792.	1.9	5
231	Coronavirus new variants: the mutations cause and the effect on the treatment and vaccination. <i>Baghdad Journal of Biochemistry and Applied Biological Sciences</i> , 2021, 2, 71-79.	0.4	9
232	Longitudinal Antibody Dynamics Against Structural Proteins of SARS-CoV-2 in Three COVID-19 Patients Shows Concurrent Development of IgA, IgM, and IgG. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 2497-2506.	1.6	9
233	Unraveling the Mystery Surrounding Post-Acute Sequelae of COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 686029.	2.2	152
234	Decay of Fc-dependent antibody functions after mild to moderate COVID-19. <i>Cell Reports Medicine</i> , 2021, 2, 100296.	3.3	56
236	COVID-19 in a Post-transplant Heart Recipient Who Developed Aggressive Lymphoma: A Biphasic Course During Rituximab Treatment. <i>HemaSphere</i> , 2021, 5, e592.	1.2	4
237	SARS-CoV-2 Genetic Variability and Non-Specific Immunity Associated with the Use of Different BCG Strains—A Molecular and Clinical Approach. <i>Vaccines</i> , 2021, 9, 639.	2.1	3
238	Science's Response to CoVID-19. <i>ChemMedChem</i> , 2021, 16, 2288-2314.	1.6	15
239	Comparative genomic analysis demonstrates that true reinfection following SARS-CoV-2 infection is possible. <i>Journal of Clinical Virology Plus</i> , 2021, 1, 100015.	0.4	0
240	Insights into SARS-CoV-2 evolution, potential antivirals, and vaccines. <i>Virology</i> , 2021, 558, 1-12.	1.1	17
241	Re-infection of SARS-CoV-2: A case in a young dental healthcare worker. <i>Journal of Infection and Public Health</i> , 2021, 14, 685-688.	1.9	6
243	Precaution, Social Distancing and Tests in a Model of Epidemic Disease. <i>B E Journal of Macroeconomics</i> , 2021, .	0.3	2
244	Critical Presentation of a Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection: A Case Report. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab329.	0.4	7

#	ARTICLE	IF	CITATIONS
245	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Sequence Characteristics of Coronavirus Disease 2019 (COVID-19) Persistence and Reinfection. <i>Clinical Infectious Diseases</i> , 2022, 74, 237-245.	2.9	59
246	An Overview About the Role of Adaptive Immunity in Keeping SARS-CoV-2 Reinfections at Bay. <i>Viral Immunology</i> , 2021, 34, 588-596.	0.6	2
247	Kidney Transplantation in COVID Pandemic—A Review of Guidelines. <i>Journal of Clinical Medicine</i> , 2021, 10, 2877.	1.0	6
248	Reinfection or Reactivation of Severe Acute Respiratory Syndrome Coronavirus 2: A Systematic Review. <i>Frontiers in Public Health</i> , 2021, 9, 663045.	1.3	29
249	Details of SARS-CoV-2 reinfections at a major UK tertiary centre. <i>Journal of Infection</i> , 2021, 82, e29-e30.	1.7	7
251	SARS-CoV-2 antibody dynamics and transmission from community-wide serological testing in the Italian municipality of Voê™. <i>Nature Communications</i> , 2021, 12, 4383.	5.8	33
252	Mathematical modelling of the second wave of COVID-19 infections using deterministic and stochastic SIRD models. <i>Nonlinear Dynamics</i> , 2021, 106, 1359-1373.	2.7	8
253	Reinfection or relapse of COVID-19 in health care workers; case series of 2 patients from Pakistan. <i>New Microbes and New Infections</i> , 2021, 42, 100896.	0.8	2
254	Evidence of SARS-CoV-2 reinfection within the same clade in Ecuador: A case study. <i>International Journal of Infectious Diseases</i> , 2021, 108, 53-56.	1.5	12
255	ACoRE: Accurate SARS-CoV-2 genome reconstruction for the characterization of intra-host and inter-host viral diversity in clinical samples and for the evaluation of re-infections. <i>Genomics</i> , 2021, 113, 1628-1638.	1.3	8
256	Antibody response after one and two jabs of the BNT162b2 vaccine in nursing home residents: The CONSORTâ€19 study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 271-281.	2.7	30
257	SARSâ€CoVâ€2 reinfection in a cancer patient with a defective neutralizing humoral response. <i>Journal of Medical Virology</i> , 2021, 93, 6444-6446.	2.5	10
258	Conundrum of re-positive COVID-19 cases: A systematic review of case reports and case series. <i>Medical Journal Armed Forces India</i> , 2021, 77, S413-S423.	0.3	1
259	Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection. <i>PLoS ONE</i> , 2021, 16, e0253977.	1.1	35
260	Postinfectious Immunity After COVID-19 and Vaccination Against SARS-CoV-2. <i>Viral Immunology</i> , 2021, 34, 504-509.	0.6	5
261	Modeling neutral viral mutations in the spread of SARS-CoV-2 epidemics. <i>PLoS ONE</i> , 2021, 16, e0255438.	1.1	13
262	Genome-Wide Variation in Betacoronaviruses. <i>Journal of Virology</i> , 2021, 95, e0049621.	1.5	4
264	Recurrent and persistent infection with SARS-CoV-2 â€ epidemiological data and case reports from Western Sweden, 2020. <i>Infectious Diseases</i> , 2021, 53, 900-907.	1.4	13

#	ARTICLE	IF	CITATIONS
265	Distinguishing repeated polymerase chain reaction positivity from reinfections in COVID-19. <i>Influenza and Other Respiratory Viruses</i> , 2021, 15, 742-749.	1.5	1
266	Resuming Clinical Teaching in the Era of COVID-19: Experiences and Protocols from a Dental School in Malaysia. <i>Sains Malaysiana</i> , 2021, 50, 2123-2134.	0.3	4
268	Severe reinfection with severe acute respiratory syndrome coronavirus 2 in a nursing home resident: a case report. <i>Journal of Medical Case Reports</i> , 2021, 15, 392.	0.4	3
269	Host- and Species-Dependent Quasispecies Divergence of Severe Acute Respiratory Syndrome Coronavirus-2 in Non-human Primate Models. <i>Frontiers in Microbiology</i> , 2021, 12, 694897.	1.5	1
270	Diagnostic Applications for RNA-Seq Technology and Transcriptome Analyses in Human Diseases Caused by RNA Viruses. , 0, , .		0
271	COVID-19 false dichotomies and a comprehensive review of the evidence regarding public health, COVID-19 symptomatology, SARS-CoV-2 transmission, mask wearing, and reinfection. <i>BMC Infectious Diseases</i> , 2021, 21, 710.	1.3	118
272	Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp13 helicase. <i>Biochemical Journal</i> , 2021, 478, 2405-2423.	1.7	46
274	Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations. <i>Vaccines</i> , 2021, 9, 773.	2.1	25
275	Acceptance of COVID-19 Vaccine in Pakistan: A Nationwide Cross-Sectional Study. <i>Cureus</i> , 2021, 13, e16603.	0.2	11
276	Beyond the new normal: Assessing the feasibility of vaccine-based suppression of SARS-CoV-2. <i>PLoS ONE</i> , 2021, 16, e0254734.	1.1	12
277	Is increased mortality by multiple exposures to COVID-19 an overseen factor when aiming for herd immunity?. <i>PLoS ONE</i> , 2021, 16, e0253758.	1.1	8
278	SARS-CoV-2 antibody kinetics eight months from COVID-19 onset: Persistence of spike antibodies but loss of neutralizing antibodies in 24% of convalescent plasma donors. <i>European Journal of Internal Medicine</i> , 2021, 89, 87-96.	1.0	53
279	Mental health of older people in social isolation: the role of physical activity at home during the COVID-19 pandemic. <i>Sport Sciences for Health</i> , 2022, 18, 597-602.	0.4	13
280	COVID-19 Subunit Vaccine with a Combination of TLR1/2 and TLR3 Agonists Induces Robust and Protective Immunity. <i>Vaccines</i> , 2021, 9, 957.	2.1	19
281	A case of COVID-19 Reinfection and Systematic Review of Patterns of Reinfection. <i>Infectious Diseases in Clinical Practice</i> , 2021, 29, e409-e411.	0.1	3
282	Incidence of COVID-19 recurrence among large cohort of healthcare employees. <i>Annals of Epidemiology</i> , 2021, 60, 8-14.	0.9	9
283	Immunity to SARS-CoV-2 induced by infection or vaccination. <i>Journal of Internal Medicine</i> , 2022, 291, 32-50.	2.7	97
284	Two-Step In Vitro Model to Evaluate the Cellular Immune Response to SARS-CoV-2. <i>Cells</i> , 2021, 10, 2206.	1.8	4

#	ARTICLE	IF	CITATIONS
285	Burden and characteristics of COVID-19 in the United States during 2020. <i>Nature</i> , 2021, 598, 338-341.	13.7	126
286	Return to Activity After SARS-CoV-2 Infection: Cardiac Clearance for Children and Adolescents. <i>Sports Health</i> , 2022, 14, 460-465.	1.3	7
287	Home alone? Effect of weather-induced behaviour on spread of SARS-CoV-2 in Germany. <i>Economics and Human Biology</i> , 2021, 42, 100998.	0.7	3
288	Safety and humoral responses to BNT162b2 mRNA vaccination of SARS-CoV-2 previously infected and naive populations. <i>Scientific Reports</i> , 2021, 11, 16543.	1.6	14
289	Targeting SARS-CoV-2 Nsp3 macrodomain structure with insights from human poly(ADP-ribose) glycohydrolase (PARG) structures with inhibitors. <i>Progress in Biophysics and Molecular Biology</i> , 2021, 163, 171-186.	1.4	39
290	COVID-19: The Disease, the Immunological Challenges, the Treatment with Pharmaceuticals and Low-Dose Ionizing Radiation. <i>Cells</i> , 2021, 10, 2212.	1.8	4
292	Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 disease. <i>PLoS ONE</i> , 2021, 16, e0255335.	1.1	48
293	Host Genetic Analysis Should Be Mandatory for Proper Classification of COVID-19 Reinfections. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab402.	0.4	1
295	COVID-19 Reinfection in a Young Medical Doctor: A Case Report. <i>Journal of the Nepal Medical Association</i> , 2021, 59, 712-715.	0.1	0
296	Application of Optimal Control of Infectious Diseases in a Model-Free Scenario. <i>SN Computer Science</i> , 2021, 2, 405.	2.3	3
297	Genomics-informed responses in the elimination of COVID-19 in Victoria, Australia: an observational, genomic epidemiological study. <i>Lancet Public Health</i> , The, 2021, 6, e547-e556.	4.7	53
298	Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection Cases Corroborated by Sequencing. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, , .	0.6	8
299	COVID-19 Research: Lessons from Non-Human Primate Models. <i>Vaccines</i> , 2021, 9, 886.	2.1	15
301	Incidence of SARS-CoV-2 infection in health care workers from Northern Italy based on antibody status: immune protection from secondary infection- A retrospective observational case-controlled study. <i>International Journal of Infectious Diseases</i> , 2021, 109, 199-202.	1.5	20
302	Immune response to SARS-CoV-2 in children: A review of the current knowledge. <i>Pediatric Investigation</i> , 2021, 5, 217-228.	0.6	17
303	A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 1652-1661.	5.7	24
304	Essential considerations during vaccine design against COVID-19 and review of pioneering vaccine candidate platforms. <i>International Immunopharmacology</i> , 2021, 97, 107679.	1.7	9
305	Development and Evaluation of a Set of Spike and Receptor Binding Domain-Based Enzyme-Linked Immunosorbent Assays for SARS-CoV-2 Serological Testing. <i>Diagnostics</i> , 2021, 11, 1506.	1.3	10

#	ARTICLE	IF	CITATIONS
306	Risk factors for SARS-CoV-2 infection and epidemiological profile of Brazilian anesthesiologists during the COVID-19 pandemic: cross-sectional study. <i>Brazilian Journal of Anesthesiology</i> (Elsevier), 2021, , .	0.2	3
307	Persistence of immunity to SARS-CoV-2 over time in the ski resort Ischgl. <i>EBioMedicine</i> , 2021, 70, 103534.	2.7	15
308	Anti-SARS-CoV-2 Antibody Levels Measured by the AdviseDx SARS-CoV-2 Assay Are Concordant with Previously Available Serologic Assays but Are Not Fully Predictive of Sterilizing Immunity. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0098921.	1.8	48
310	Modelling and optimal control of multi strain epidemics, with application to COVID-19. <i>PLoS ONE</i> , 2021, 16, e0257512.	1.1	46
311	Planned Pregnancy in Kidney Transplantation. A Calculated Risk. <i>Journal of Personalized Medicine</i> , 2021, 11, 956.	1.1	6
313	Containing epidemics in a local cluster via antidote distribution and partial quarantine. <i>Physical Review E</i> , 2021, 104, 034307.	0.8	0
314	Late reinfection with a different severe acute respiratory syndrome coronavirus-2 clade in a patient with refractory arterial hypertension: a case report. <i>Journal of Medical Case Reports</i> , 2021, 15, 454.	0.4	0
317	Effective vaccine allocation strategies, balancing economy with infection control against COVID-19 in Japan. <i>PLoS ONE</i> , 2021, 16, e0257107.	1.1	17
318	SARS-CoV-2: lessons from both the history of medicine and from the biological behavior of other well-known viruses. <i>Future Microbiology</i> , 2021, 16, 1105-1133.	1.0	11
319	The protective effect of previous COVID-19 infection in a high-prevalence hospital setting. <i>Clinical Medicine</i> , 2021, 21, e470-e474.	0.8	4
320	Seroprevalence of SARS-CoV-2 antibodies and reduced risk of reinfection through 6 months: a Danish observational cohort study of 44000 healthcare workers. <i>Clinical Microbiology and Infection</i> , 2022, 28, 710-717.	2.8	9
321	SARS-CoV-2 reinfection in patients negative for immunoglobulin G following recovery from COVID-19. <i>New Microbes and New Infections</i> , 2021, 43, 100926.	0.8	34
322	COVID-19 Animal Models and Vaccines: Current Landscape and Future Prospects. <i>Vaccines</i> , 2021, 9, 1082.	2.1	8
323	Reinfection cases by closely related SARS-CoV-2 lineages in Southern Brazil. <i>Brazilian Journal of Microbiology</i> , 2021, 52, 1881-1885.	0.8	2
324	Complexities in Case Definition of SARS-CoV-2 Reinfection: Clinical Evidence and Implications in COVID-19 Surveillance and Diagnosis. <i>Pathogens</i> , 2021, 10, 1262.	1.2	0
325	Case report: change of dominant strain during dual SARS-CoV-2 infection. <i>BMC Infectious Diseases</i> , 2021, 21, 959.	1.3	32
326	Complete Analysis of the Epidemiological Scenario around a SARS-CoV-2 Reinfection: Previous Infection Events and Subsequent Transmission. <i>MSphere</i> , 2021, 6, e0059621.	1.3	4
327	People living with HIV easily lose their immune response to SARS-CoV-2: result from a cohort of COVID-19 cases in Wuhan, China. <i>BMC Infectious Diseases</i> , 2021, 21, 1029.	1.3	15

#	ARTICLE	IF	CITATIONS
328	New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil. <i>Infection, Genetics and Evolution</i> , 2021, 94, 104998.	1.0	22
329	Research on bilingualism as discovery science. <i>Brain and Language</i> , 2021, 222, 105014.	0.8	24
330	Immune response variables and viral mutations impact on COVID-19 reinfection and relapse. <i>International Immunopharmacology</i> , 2021, 100, 108108.	1.7	7
331	SARS-CoV-2 reinfection in a healthcare professional in inner Sao Paulo during the first wave of COVID-19 in Brazil. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 101, 115516.	0.8	9
332	COVID-19 challenges: From SARS-CoV-2 infection to effective point-of-care diagnosis by electrochemical biosensing platforms. <i>Biochemical Engineering Journal</i> , 2021, 176, 108200.	1.8	17
333	Modelling COVID-19 dynamics and potential for herd immunity by vaccination in Austria, Luxembourg and Sweden. <i>Journal of Theoretical Biology</i> , 2021, 530, 110874.	0.8	22
335	Evolving Patterns in COVID-19: The Virus, its Variants and Infectivity-cum-Virulence. <i>Biomedical Journal of Scientific & Technical Research</i> , 2021, 33, .	0.0	3
336	The COVID-19 second wave: A perspective to be explored. <i>Brazilian Journal of Infectious Diseases</i> , 2021, 25, 101537.	0.3	20
338	Asymptomatic reactivation of SARS-CoV-2 in a child with neuroblastoma characterised by whole genome sequencing. <i>IDCases</i> , 2021, 23, e01018.	0.4	9
339	(RE) currences in COVID-19: (RE)-activation or (RE)-infection?. <i>Journal of Family Medicine and Primary Care</i> , 2021, 10, 1525.	0.3	2
340	The Anxiety of COVID and the Epidemic of Fear. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
341	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunity and Reinfection. <i>Clinical Infectious Diseases</i> , 2021, 73, e2992-e2994.	2.9	11
343	siRNA Therapeutics against Respiratory Viral Infectionsâ€”What Have We Learned for Potential COVIDâ€™19 Therapies?. <i>Advanced Healthcare Materials</i> , 2021, 10, e2001650.	3.9	47
344	Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in golden Syrian hamster. <i>Emerging Microbes and Infections</i> , 2021, 10, 797-809.	3.0	42
345	Epidemiology of COVID-19 in Latin America. , 2021, , 11-24.		0
346	Early detection of SARS-CoV-2 P.1 variant in Southern Brazil and reinfection of the same patient by P.2. <i>Revista Do Instituto De Medicina Tropical De Sao Paulo</i> , 2021, 63, e58.	0.5	31
347	6-month SARS-CoV-2 antibody persistency in aÄ™Tyrolian COVID-19 cohort. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 351-358.	1.0	10
348	Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?. <i>Science China Life Sciences</i> , 2020, 63, 1833-1849.	2.3	29

#	ARTICLE	IF	CITATIONS
349	Immune characteristics analysis reveals two key inflammatory factors correlated to the expressions of SARS-CoV-2 S1-specific antibodies. <i>Genes and Diseases</i> , 2020, , .	1.5	6
350	Innate Immunity Plays a Key Role in Controlling Viral Load in COVID-19: Mechanistic Insights from a Whole-Body Infection Dynamics Model. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 248-265.	2.5	36
351	Clinical and Laboratory Findings in Patients With Potential Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection, May-July 2020. <i>Clinical Infectious Diseases</i> , 2021, 73, 2217-2225.	2.9	17
352	SARS-CoV-2 Serologic Assays in Control and Unknown Populations Demonstrate the Necessity of Virus Neutralization Testing. <i>Journal of Infectious Diseases</i> , 2021, 223, 1120-1131.	1.9	27
369	Long-term kinetics of anti-SARS-CoV-2 antibodies in a cohort of 197 hospitalized and non-hospitalized COVID-19 patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, e179-e183.	1.4	15
370	Slums and Pandemics. <i>SSRN Electronic Journal</i> , 0, , .	0.4	9
371	A case of COVID-19 reinfection in the UK. <i>Clinical Medicine</i> , 2021, 21, e52-e53.	0.8	52
372	Immunology of SARS-CoV-2 infections and vaccines. <i>Advances in Immunology</i> , 2021, 151, 49-97.	1.1	12
373	Testing Positive for SARS-CoV-2 in Two Countries 105 Days Apart. <i>Prague Medical Report</i> , 2021, 122, 228-232.	0.4	0
374	OUP accepted manuscript. <i>Briefings in Functional Genomics</i> , 2021, , .	1.3	2
375	Persistence and viability of SARS-CoV-2 in primary infection and reinfections. <i>Revista Espanola De Quimioterapia</i> , 2022, 35, 1-6.	0.5	4
376	The SARS-CoV-2 pandemic: remaining uncertainties in our understanding of the epidemiology and transmission dynamics of the virus, and challenges to be overcome. <i>Interface Focus</i> , 2021, 11, 20210008.	1.5	24
377	Changes in COVID-19 vaccine acceptance rate among recovered critically ill patients: A 12-month follow-up study. <i>Vaccine</i> , 2021, 39, 7074-7081.	1.7	5
378	Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1450-1466.	5.2	110
379	SARS-CoV-2 Reinfection Is a New Challenge for the Effectiveness of Global Vaccination Campaign: A Systematic Review of Cases Reported in Literature. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 11001.	1.2	14
381	COVID-19 cynomolgus macaque model reflecting human COVID-19 pathological conditions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	26
382	Reinfections in COVID-19 Patients: Impact of Virus Genetic Variability and Host Immunity. <i>Vaccines</i> , 2021, 9, 1168.	2.1	19
383	Uncertainty around the Long-Term Implications of COVID-19. <i>Pathogens</i> , 2021, 10, 1267.	1.2	16

#	ARTICLE	IF	CITATIONS
384	Economic Irreversibility in Pandemic Control Processes: Rigorous Modeling of Delayed Countermeasures and Consequential Cost Increases. <i>Journal of the Physical Society of Japan</i> , 2021, 90, .	0.7	2
385	Assessing the effects of non-pharmaceutical interventions on SARS-CoV-2 transmission in Belgium by means of an extended SEIQRD model and public mobility data. <i>Epidemics</i> , 2021, 37, 100505.	1.5	20
387	Clinical outcomes of sofosbuvir-based antivirals in patients with COVID-19: a systematic review and meta-analysis of randomized trials. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 567-575.	2.0	6
388	Synergistic interventions to control COVID-19: Mass testing and isolation mitigates reliance on distancing. <i>PLoS Computational Biology</i> , 2021, 17, e1009518.	1.5	8
389	Longitudinal Immune Profiling of a Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection in a Solid Organ Transplant Recipient. <i>Journal of Infectious Diseases</i> , 2022, 225, 374-384.	1.9	7
391	Política da vacina e irresponsabilidade sanitária. <i>Cadernos Ibero-americanos De Direito Sanitário</i> , 2020, 9, 192-197.	0.1	2
394	Implication of SARS-CoV-2 Immune Escape Spike Variants on Secondary and Vaccine Breakthrough Infections. <i>Frontiers in Immunology</i> , 2021, 12, 742167.	2.2	32
395	Reinfection by SARS-CoV-2: The first one in a family reported in Spain. <i>Medicina Clínica (English)</i> Tj ETQq1 1 0.784314 rgBT /Overlock 1	0.1	1
396	Clinical Practice in COVID-19: the most frequently asked questions to Infectious Diseases Specialists. <i>Brazilian Journal of Infectious Diseases</i> , 2021, 25, 101648.	0.3	1
397	Viral Haplotypes in COVID-19 Patients Associated With Prolonged Viral Shedding. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 715143.	1.8	1
398	Gut microbiome, Vitamin D, ACE2 interactions are critical factors in immune-senescence and inflammation: key for vaccine response and severity of COVID-19 infection. <i>Inflammation Research</i> , 2022, 71, 13-26.	1.6	10
403	COVID-19: Is reinfection possible?. <i>EXCLI Journal</i> , 2021, 20, 522-536.	0.5	5
404	Update on geographical variation and distribution of SARS-nCoV-2: A systematic review. <i>Indian Journal of Pharmacology</i> , 2021, 53, 310-316.	0.4	3
406	Systematic Genomic and Clinical Analysis of Severe Acute Respiratory Syndrome Coronavirus 2 Reinfections and Recurrences Involving the Same Strain. <i>Emerging Infectious Diseases</i> , 2022, 28, 86-95.	2.0	8
407	Patterns of SARS-CoV-2 Testing Preferences in a National Cohort in the United States: Latent Class Analysis of a Discrete Choice Experiment. <i>JMIR Public Health and Surveillance</i> , 2021, 7, e32846.	1.2	5
408	The use of neutralizing monoclonal antibodies and risk of hospital admission and mortality in patients with COVID-19: a systematic review and meta-analysis of randomized trials. <i>Immunopharmacology and Immunotoxicology</i> , 2022, 44, 28-34.	1.1	16
410	PD-1 blockade counteracts post-COVID-19 immune abnormalities and stimulates the anti-SARS-CoV-2 immune response. <i>JCI Insight</i> , 2021, 6, .	2.3	51
411	Infection and transmission of ancestral SARS-CoV-2 and its alpha variant in pregnant white-tailed deer. <i>Emerging Microbes and Infections</i> , 2022, 11, 95-112.	3.0	77

#	ARTICLE	IF	CITATIONS
413	Immunological Biomarkers in Blood to Monitor the Course and Therapeutic Outcomes of COVID-19. Therapeutic Drug Monitoring, 2021, Publish Ahead of Print, .	1.0	1
414	SARS-CoV-2 infection and oxidative stress: Pathophysiological insight into thrombosis and therapeutic opportunities. Cytokine and Growth Factor Reviews, 2022, 63, 44-57.	3.2	41
415	Infection in asymptomatic carriers of SARS-CoV-2 can interfere with the achievement of robust immunity on a population scale. Journal of General Virology, 2021, 102, .	1.3	0
416	A case with SARS-CoV-2 reinfection from India. Indian Journal of Medical Microbiology, 2021, 40, 166-166.	0.3	3
417	Identifying Inconclusive Data in the SARS-CoV-2 Molecular Diagnostic Using Nucleocapsid Phosphoprotein Gene as a Target. Archives of Pathology and Laboratory Medicine, 2022, 146, 272-277.	1.2	4
418	Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection Associates With Unstable Housing and Occurs in the Presence of Antibodies. Clinical Infectious Diseases, 2022, 75, e208-e215.	2.9	16
420	Molecularly imprinted polypyrrole based sensor for the detection of SARS-CoV-2 spike glycoprotein. Electrochimica Acta, 2022, 403, 139581.	2.6	99
421	COVID-19 reinfection: the role of natural immunity, vaccines, and variants. Journal of Community Hospital Internal Medicine Perspectives, 2021, 11, 733-739.	0.4	22
422	Activity-based epidemic propagation and contact network scaling in auto-dependent metropolitan areas. Scientific Reports, 2021, 11, 22665.	1.6	3
423	Second SARS-CoV-2 infections twelve months after initial infections in Australia, confirmed by genomic analysis. Medical Journal of Australia, 2021, , .	0.8	2
424	â€œI took it off most of the time 'cause I felt comfortableâ€ unmasking, trusted others, and lessons learned from a coronavirus disease 2019 reinfection: a case report. Journal of Medical Case Reports, 2021, 15, 557.	0.4	1
425	SARS-CoV-2 re-infection rate in Iranian COVID-19 cases within one-year follow-up. Microbial Pathogenesis, 2021, 161, 105296.	1.3	23
426	Genomic evidence of SARS-CoV-2 reinfection in the Republic of Korea. Journal of Medical Virology, 2022, 94, 1717-1722.	2.5	2
427	Drug-based therapeutic strategies for COVID-19-infected patients and their challenges. Future Microbiology, 2021, 16, 1415-1451.	1.0	12
428	The mystery of COVID-19 reinfections: A global systematic review and meta-analysis. Annals of Medicine and Surgery, 2021, 72, 103130.	0.5	31
429	Reinfection with new variants of SARS-CoV-2 after natural infection: a prospective observational cohort in 13 care homes in England. The Lancet Healthy Longevity, 2021, 2, e811-e819.	2.0	54
430	Six-month outcomes and effect of pulmonary rehabilitation among patients hospitalized with COVID-19: a retrospective cohort study. Annals of Medicine, 2021, 53, 2099-2109.	1.5	16
431	Seroprevalence and attainment of herd immunity against SARS CoV-2: A modelling study. Journal of Family Medicine and Primary Care, 2021, 10, 4030.	0.3	0

#	ARTICLE	IF	CITATIONS
432	Should Breakthrough SARS-CoV-2 Infection Affect Our Confidence in the COVID-19 Vaccines?. <i>Infection and Chemotherapy</i> , 2021, 53, 676.	1.0	7
434	Dynamic data-driven algorithm to predict cumulative COVID-19 infected cases using susceptible-infected-susceptible model. <i>Epidemiologic Methods</i> , 2021, 10, .	0.8	3
436	Evaluation of Reinfection in COVID-19 Patients in the World: A Narrative Review. <i>Medical Journal of the Islamic Republic of Iran</i> , 2021, 35, 144.	0.9	1
437	How immunity from and interaction with seasonal coronaviruses can shape SARS-CoV-2 epidemiology. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	18
438	A multi-source global-local model for epidemic management. <i>PLoS ONE</i> , 2022, 17, e0261650.	1.1	1
439	Serological Markers of SARS-CoV-2 Reinfection. <i>MBio</i> , 2022, 13, e0214121.	1.8	8
440	Three waves changes, new variant strains, and vaccination effect against COVID-19 pandemic. <i>International Journal of Biological Macromolecules</i> , 2022, 204, 161-168.	3.6	147
441	A lethal mouse model for evaluating vaccine-associated enhanced respiratory disease during SARS-CoV-2 infection. <i>Science Advances</i> , 2022, 8, eabh3827.	4.7	27
442	Nine-month course of SARS-CoV-2 antibodies in individuals with COVID-19 infection. <i>Irish Journal of Medical Science</i> , 2022, 191, 2803-2811.	0.8	6
443	Update to COVID-19 serologic testing : FAQs and caveats. <i>Cleveland Clinic Journal of Medicine</i> , 2022, , .	0.6	3
445	Trajectory of Viral RNA Load Among Persons With Incident SARS-CoV-2 G614 Infection (Wuhan Strain) in Association With COVID-19 Symptom Onset and Severity. <i>JAMA Network Open</i> , 2022, 5, e2142796.	2.8	57
446	The chance of COVID-19 infection after vaccination. <i>Infectious Disorders - Drug Targets</i> , 2022, 22, .	0.4	0
447	Partial remission of advanced untreated SÅ©zary syndrome after COVID-19. <i>JAAD Case Reports</i> , 2022, 21, 165-168.	0.4	2
449	Persistence of Anti-SARS-CoV-2 Antibodies in Long Term Care Residents Over Seven Months After Two COVID-19 Outbreaks. <i>Frontiers in Immunology</i> , 2021, 12, 775420.	2.2	8
450	Immune dynamics of SARS-CoV-2 virus evolution. <i>International Journal of Molecular and Immuno Oncology</i> , 0, 7, 3-15.	0.0	2
451	COVID-19 reinfections among naturally infected and vaccinated individuals. <i>Scientific Reports</i> , 2022, 12, 1438.	1.6	79
452	Neutralizing Antibodies and Antibody-Dependent Enhancement in COVID-19: A Perspective. <i>Journal of the Indian Institute of Science</i> , 2022, , 1-17.	0.9	12
453	Immune response to SARS-CoV-2 variants: A focus on severity, susceptibility, and preexisting immunity. <i>Journal of Infection and Public Health</i> , 2022, 15, 277-288.	1.9	21

#	ARTICLE	IF	CITATIONS
454	SARS-CoV-2 transmission in opposition-controlled Northwest Syria: modeling pandemic responses during political conflict. <i>International Journal of Infectious Diseases</i> , 2022, 117, 103-115.	1.5	8
455	Quantifying Neutralizing Antibodies in Patients with COVID-19 by a Two-Variable Generalized Additive Model. <i>MSphere</i> , 2022, 7, e0088321.	1.3	10
456	Recurrent COVID-19 Polymerase Chain Reaction (PCR) Positivity in 2 Patients During the Current Health Care System Crisis. <i>American Journal of Case Reports</i> , 2022, 23, e935414.	0.3	1
458	Reinfection with SARS-CoV-2: An inconvenient truth?. <i>Journal of Family Medicine and Primary Care</i> , 2022, 11, 366.	0.3	1
459	Development of SARS-CoV2 humoral response including neutralizing antibodies is not sufficient to protect patients against fatal infection. <i>Scientific Reports</i> , 2022, 12, 2077.	1.6	8
460	Characterising within-hospital SARS-CoV-2 transmission events using epidemiological and viral genomic data across two pandemic waves. <i>Nature Communications</i> , 2022, 13, 671.	5.8	33
461	Therapeutics for COVID-19 and post COVID-19 complications: An update. <i>Current Research in Pharmacology and Drug Discovery</i> , 2022, 3, 100086.	1.7	55
462	Sequencing SARS-CoV-2 from antigen tests. <i>PLoS ONE</i> , 2022, 17, e0263794.	1.1	11
463	Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2 experienced individuals. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	65
464	State specific estimates of vaccine hesitancy among US adults. <i>Population Medicine</i> , 2021, 3, 1-9.	0.3	4
465	Recurrent SARS-CoV-2 infections and their potential risk to public health – a systematic review. <i>PLoS ONE</i> , 2021, 16, e0261221.	1.1	9
466	A Case Report: Genetically Distinct Severe Acute Respiratory Syndrome Coronavirus-2 Variant Causing Reinfection. <i>Frontiers in Microbiology</i> , 2021, 12, 792514.	1.5	2
467	Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2 experienced individuals. <i>Science Translational Medicine</i> , 2021, , eabi8961.	5.8	22
468	Future-proofing and maximizing the utility of metadata: The PHA4GE SARS-CoV-2 contextual data specification package. <i>GigaScience</i> , 2022, 11, .	3.3	18
469	SARS-CoV-2 Reinfection Rate and Outcomes in Saudi Arabia: A National Retrospective Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
470	Both simulation and sequencing data reveal coinfections with multiple SARS-CoV-2 variants in the COVID-19 pandemic. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 1389-1401.	1.9	7
472	Durable T-cellular and humoral responses in SARS-CoV-2 hospitalized and community patients. <i>PLoS ONE</i> , 2022, 17, e0261979.	1.1	10
473	Antibody attributes that predict the neutralization and effector function of polyclonal responses to SARS-CoV-2. <i>BMC Immunology</i> , 2022, 23, 7.	0.9	6

#	ARTICLE	IF	CITATIONS
474	Nasal Nanovaccines for SARS-CoV-2 to Address COVID-19. <i>Vaccines</i> , 2022, 10, 405.	2.1	14
475	SARS-CoV-2 Point Mutation and Deletion Spectra and Their Association with Different Disease Outcomes. <i>Microbiology Spectrum</i> , 2022, 10, e0022122.	1.2	10
476	Why Controlling the Asymptomatic Infection Is Important: A Modelling Study with Stability and Sensitivity Analysis. <i>Fractal and Fractional</i> , 2022, 6, 197.	1.6	10
477	Immune durability and protection against SARS-CoV-2 re-infection in Syrian hamsters. <i>Emerging Microbes and Infections</i> , 2022, 11, 1103-1114.	3.0	11
478	A Recombinant Subunit Vaccine Induces a Potent, Broadly Neutralizing, and Durable Antibody Response in Macaques against the SARS-CoV-2 P.1 (Gamma) Variant. <i>ACS Infectious Diseases</i> , 2022, 8, 825-840.	1.8	3
480	Protective Immunity of the Primary SARS-CoV-2 Infection Reduces Disease Severity Post Re-Infection with Delta Variants in Syrian Hamsters. <i>Viruses</i> , 2022, 14, 596.	1.5	6
481	How to Motivate SARS-CoV-2 Convalescents to Receive a Booster Vaccination? Influence on Vaccination Willingness. <i>Vaccines</i> , 2022, 10, 455.	2.1	9
482	The Effect of Varying Interval Definitions on the Prevalence of SARS-CoV-2 Reinfections: A Retrospective Cross-Sectional Cohort Study. <i>Diagnostics</i> , 2022, 12, 719.	1.3	1
483	Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology. <i>Immunity, Inflammation and Disease</i> , 2022, 10, e595.	1.3	6
484	Recurrence of Asymptomatic COVID-19 after Recovery among Healthcare Workers. <i>Case Reports in Infectious Diseases</i> , 2022, 2022, 1-5.	0.2	0
485	Correlation between chest CT scores and clinical impact in patients re-infected with COVID-19 during the two attacks: an observational study. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2022, 53, .	0.3	0
486	Reinfection in COVID-19: Do we exaggerate our worries?. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13767.	1.7	11
487	Screening Large Population Health Databases for Potential Coronavirus Disease 2019 Therapeutics: A Pharmacopeia-Wide Association Study of Commonly Prescribed Medications. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac156.	0.4	1
488	SARS-CoV-2 reinfection prevents acute respiratory disease in Syrian hamsters but not replication in the upper respiratory tract. <i>Cell Reports</i> , 2022, 38, 110515.	2.9	16
489	Performance of electrochemical immunoassays for clinical diagnostics of SARS-CoV-2 based on selective nucleocapsid N protein detection: Boron-doped diamond, gold and glassy carbon evaluation. <i>Biosensors and Bioelectronics</i> , 2022, 209, 114222.	5.3	23
490	Clinical manifestations, treatment options, and comorbidities in COVID-19 relapse patients: A systematic review. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24402.	0.9	11
491	Synopsis of symptoms of COVID-19 during second wave of the pandemic in India. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2022, 43, 97-104.	0.3	6
492	Hypothetical Immunological and Immunogenetic Model of Heterogenous Effects of BCG Vaccination in SARS-CoV-2 Infections: BCG-induced Trained and Heterologous Immunity. <i>Journal of Medical Science</i> , 0, e551.	0.2	2

#	ARTICLE	IF	CITATIONS
493	Durability of Humoral Immune Responses to SARS-CoV-2 in Citizens of Ariano Irpino (Campania, Italy): A Longitudinal Observational Study With an 11.5-Month Follow-Up. <i>Frontiers in Public Health</i> , 2021, 9, 801609.	1.3	5
494	A 63-Year-Old Man with a Diagnosis of Re-Infection with SARS-CoV-2 Nine Weeks After an Initial Hospital Admission with COVID-19 Pneumonia. <i>American Journal of Case Reports</i> , 2022, 23, e932999.	0.3	0
495	RT-PCR Detection of SARS-CoV-2 among Individuals from the Upper Silesian Region—Analysis of 108,516 Tests. <i>Diagnostics</i> , 2022, 12, 7.	1.3	3
496	COVID-19 vaccination strategies depend on the underlying network of social interactions. <i>Scientific Reports</i> , 2021, 11, 24051.	1.6	7
497	Rapidly Self-Sterilizing PPE Capable of Destroying 100% of Microbes in 30-60 Seconds. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 752899.	1.8	1
498	SARS-CoV-2: Some Aspects of Molecular Evolution, Cellular Pathogenesis, and Immune System Mechanism Elusion. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 11605.	1.3	3
499	An update on host immunity correlates and prospects of re-infection in COVID-19. <i>International Reviews of Immunology</i> , 2022, 41, 367-392.	1.5	9
500	COVID-19 Vaccination: The Mainspring of Challenges and the Seed of Remonstrance. <i>Vaccines</i> , 2021, 9, 1474.	2.1	6
501	Reinfection rates among patients previously infected by SARS-CoV-2: systematic review and meta-analysis. <i>Chinese Medical Journal</i> , 2022, 135, 145-152.	0.9	35
502	Mechanical dependency of the SARS-CoV-2 virus and the renin-angiotensin-aldosterone (RAAS) axis: a possible new threat. <i>Environmental Science and Pollution Research</i> , 2021, , 1.	2.7	2
504	COVID-19 infection recurrence in ESRD. <i>Indian Journal of Nephrology</i> , 2022, 32, 184.	0.2	0
505	Immunopathogenesis of patients with COVID-19: from the perspective of immune system “evolution” and “revolution”. <i>Expert Reviews in Molecular Medicine</i> , 2022, 24, e19.	1.6	3
506	SARS-CoV-2 vaccine breakthrough reinfection in a health-care worker of Iraq: A case report. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-3.	1.4	2
507	4-fluorouridine and its derivatives as potential COVID-19 oral drugs: a review. <i>F1000Research</i> , 0, 11, 410.	0.8	3
508	Long-Term, CD4+ Memory T Cell Response to SARS-CoV-2. <i>Frontiers in Immunology</i> , 2022, 13, 800070.	2.2	12
509	Use of wastewater surveillance for early detection of Alpha and Epsilon SARS-CoV-2 variants of concern and estimation of overall COVID-19 infection burden. <i>Science of the Total Environment</i> , 2022, 835, 155410.	3.9	34
510	Phylogenetic and phylodynamic approaches to understanding and combating the early SARS-CoV-2 pandemic. <i>Nature Reviews Genetics</i> , 2022, 23, 547-562.	7.7	70
511	Recurrent SARS-CoV-2 Infection and Impaired Immunologic Response in a Pediatric Oncologic Patient While Treated With Radiochemotherapy. <i>Pediatric Infectious Disease Journal</i> , 2022, 41, e259-e262.	1.1	1

#	ARTICLE	IF	CITATIONS
512	Assessment of COVID-19 vaccine hesitancy among Zimbabweans: A rapid national survey. PLoS ONE, 2022, 17, e0266724.	1.1	28
515	Reinfection in patients with COVID-19: a systematic review. Global Health Research and Policy, 2022, 7, 12.	1.4	53
516	Statistical Challenges in Tracking the Evolution of SARS-CoV-2. Statistical Science, 2022, 37, .	1.6	7
517	IgG targeting distinct seasonal coronavirus- conserved SARS-CoV-2 spike subdomains correlates with differential COVID-19 disease outcomes. Cell Reports, 2022, 39, 110904.	2.9	9
518	PARIS and SPARTA: Finding the Achillesâ€™ Heel of SARS-CoV-2. MSphere, 2022, 7, e0017922.	1.3	25
519	Protective effect of a first SARS-CoV-2 infection from reinfection: a matched retrospective cohort study using PCR testing data in England. Epidemiology and Infection, 2022, 150, .	1.0	8
520	Clinical Characteristics and Outcomes of Patients With SARS-CoV-2 Reinfection. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2022, 6, 361-372.	1.2	4
521	Risk of COVID-19 re-infection and its predictors (CORES): protocol for a community-based longitudinal cohort study in Vellore, India. BMJ Open, 2022, 12, e059869.	0.8	0
522	Characteristics of 24 SARS-CoV-2-Sequenced Reinfection Cases in a Tertiary Hospital in Spain. Frontiers in Microbiology, 2022, 13, .	1.5	1
523	Laboratory Diagnosis for SARS-CoV-2 Infection. Infectious Disease Clinics of North America, 2022, 36, 327-347.	1.9	4
524	Coronavirus reinfections: An outlook on evidences and effects. , 2022, , 19-40.		3
525	An Update on Protective Effectiveness of Immune Responses After Recovery From COVID-19. Frontiers in Immunology, 0, 13, .	2.2	7
526	Rapid repeat infection of SARS-CoV-2 by two highly distinct delta-lineage viruses. Diagnostic Microbiology and Infectious Disease, 2022, 104, 115747.	0.8	3
527	Accurate identification of SARS-CoV-2 variant delta using graphene/CRISPR-dCas9 electrochemical biosensor. Talanta, 2022, 249, 123687.	2.9	13
528	SARIMA model-based forecasting required number of COVID-19 vaccines globally and empirical analysis of peoplesâ€™ view towards the vaccines. AEJ - Alexandria Engineering Journal, 2022, 61, 12091-12110.	3.4	3
529	Reinfection of SARS-CoV-2 in kidney transplant recipient. Indian Journal of Transplantation, 2022, 16, 234.	0.0	0
530	Epidemiological and clinical characteristics of SARS-CoV-2 reinfections in a Spanish region. SAGE Open Medicine, 2022, 10, 205031212211085.	0.7	2
531	An agent-based model to assess large-scale COVID-19 vaccination campaigns for the Italian territory: The case study of Lombardy region. Computer Methods and Programs in Biomedicine, 2022, 224, 107029.	2.6	5

#	ARTICLE	IF	CITATIONS
532	Genomic surveillance of SARS-CoV-2 during the first year of the pandemic in the Bronx enabled clinical and epidemiological inference. <i>Journal of Physical Education and Sports Management</i> , 0, , mcs.a006211.	0.5	0
533	<scp>COVID</scp>â€19 and plasma cells: Is there longâ€lived protection?*. <i>Immunological Reviews</i> , 2022, 309, 40-63.	2.8	26
534	SARS-CoV-2 Reinfection Rate and Outcomes in Saudi Arabia: A National Retrospective Study. <i>International Journal of Infectious Diseases</i> , 2022, 122, 758-766.	1.5	15
535	Relatively rapid evolution rates of SARS-CoV-2 spike gene at the primary stage of massive vaccination. <i>Biosafety and Health</i> , 2022, 4, 228-233.	1.2	6
536	Coronaviruses. , 2023, , 277-306.		0
537	Nasal Mucosa Exploited by SARS-CoV-2 for Replicating and Shedding during Reinfection. <i>Viruses</i> , 2022, 14, 1608.	1.5	2
538	Modelling the interplay of SARS-CoV-2 variants in the United Kingdom. <i>Scientific Reports</i> , 2022, 12, .	1.6	11
539	An outbreak of SARS-CoV-2 reinfection in a long-term care facility in South Korea. <i>Journal of Infection and Public Health</i> , 2022, 15, 966-969.	1.9	6
540	Genomic evidence for divergent co-infections of co-circulating SARS-CoV-2 lineages. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 4015-4024.	1.9	14
541	Detection of SARS-CoV-2 Genome for over 100 Days after COVID-19 Onset. <i>Japanese Journal of Infectious Diseases</i> , 2022, , .	0.5	1
542	Mild reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant: First case report from Indonesia. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4
543	Characterization of the expressed RNA variants from young patients with critical and non-critical SARS-CoV-2 infection. <i>Egyptian Journal of Medical Human Genetics</i> , 2022, 23, .	0.5	0
544	Immediate reinfection with Omicron variant after clearance of a previous SARS-CoV-2 infection. <i>Journal of Infection and Public Health</i> , 2022, 15, 983-985.	1.9	6
545	Rapid Increase in Suspected SARS-CoV-2 Reinfections, Clark County, Nevada, USA, December 2021. <i>Emerging Infectious Diseases</i> , 2022, 28, 1977-1981.	2.0	8
546	Epidemiological assessment of SARS-CoV-2 reinfection. <i>International Journal of Infectious Diseases</i> , 2022, 123, 9-16.	1.5	13
547	Impact of prior SARS-CoV-2 infection and COVID-19 vaccination on the subsequent incidence of COVID-19: a multicentre prospective cohort study among UK healthcare workers â€“ the SIREN (Sarscov2) Tj ETQq0.â€ 0.784â€14 rgBT		
548	Recurrence of COVID-19 infection symptoms in short time; reinfection or reactivation? Three cases of three healthcare workers and a literature review. <i>Annals of Medicine and Surgery</i> , 2022, 82, .	0.5	0
549	COVID-19 mRNA Vaccines. , 2022, , 769-802.		0

#	ARTICLE	IF	CITATIONS
550	Humoral Immune Response in SARS-CoV-2 Infection and Its Therapeutic Relevance. , 2022, , 19-29.		0
551	Prospects of Coffee Leaf against SARS-CoV-2 Infection. International Journal of Biological Sciences, 2022, 18, 4677-4689.	2.6	7
552	SARS-CoV-2 coinfections with variant genomic lineages identified by multiplex fragment analysis. Frontiers in Genetics, 0, 13, .	1.1	5
553	SARS-CoV-2 reinfections during the first three major COVID-19 waves in Bulgaria. PLoS ONE, 2022, 17, e0274509.	1.1	8
555	Challenges and Impacts of COVID-19 Pandemic on Global Waste Management Systems: A Review. Journal of Composites Science, 2022, 6, 271.	1.4	16
556	NanoCoV19: An analytical pipeline for rapid detection of severe acute respiratory syndrome coronavirus 2. Frontiers in Genetics, 0, 13, .	1.1	2
557	A high scale SARS-CoV-2 profiling by its whole-genome sequencing using Oxford Nanopore Technology in Kazakhstan. Frontiers in Genetics, 0, 13, .	1.1	2
558	A comparison between SARS-CoV-1 and SARS-CoV2: an update on current COVID-19 vaccines. DARU, Journal of Pharmaceutical Sciences, 0, , .	0.9	5
559	Reinfection and reactivation of SARS-CoV-2. Future Virology, 2022, 17, 835-844.	0.9	5
560	Does potential antibody-dependent enhancement occur during SARS-CoV-2 infection after natural infection or vaccination? A meta-analysis. BMC Infectious Diseases, 2022, 22, .	1.3	6
561	Occurrence of SARS-CoV-2 reinfections at regular intervals in Ecuador. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	0
563	Anti-SARS-CoV-2 antibody immunoreactivity profiles during COVID-19 recurrence. Revista Da Sociedade Brasileira De Medicina Tropical, 0, 55, .	0.4	0
564	A retrospective cross-sectional observational study of SARS-CoV-2 reinfection in La Ribera Health Department, Valencia, Spain. Journal of Medical Microbiology, 2022, 71, .	0.7	1
566	Novel coronavirus mutations: Vaccine development and challenges. Microbial Pathogenesis, 2022, 173, 105828.	1.3	7
567	Who Is at Higher Risk of SARS-CoV-2 Reinfection? Results from a Northern Region of Italy. Vaccines, 2022, 10, 1885.	2.1	9
568	Targeting SARS-CoV-2 nsp13 Helicase and Assessment of Druggability Pockets: Identification of Two Potent Inhibitors by a Multi-Site In Silico Drug Repurposing Approach. Molecules, 2022, 27, 7522.	1.7	5
569	Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nature Medicine, 2022, 28, 2398-2405.	15.2	241
570	COVID-19 Relapse and Reinfection Frequency, Clinical Features of Cases. Ahi Evran Medical Journal, 0, , .	0.1	1

#	ARTICLE	IF	CITATIONS
571	Comparison of a Prototype SARS-CoV-2 Lateral Flow IMMUNOASSAY with the BinaxNOW™ COVID-19 Antigen CARD. <i>Viruses</i> , 2022, 14, 2609.	1.5	0
572	Primary SARS-CoV-2 Infections, Re-infections and Vaccine Effectiveness during the Omicron Transmission Period in Healthcare Workers of Trieste and Gorizia (Northeast Italy), 1 December 2021â€“31 May 2022. <i>Viruses</i> , 2022, 14, 2688.	1.5	11
573	Kinetics of SARS-CoV-2 IgM and IgG Antibodies 3 Months after COVID-19 Onset in Moroccan Patients. <i>American Journal of Tropical Medicine and Hygiene</i> , 2023, 108, 145-154.	0.6	6
574	Reinfection with SARS-CoV-2 and Waning Humoral Immunity: A Case Report. <i>Vaccines</i> , 2023, 11, 5.	2.1	5
575	Mutational Patterns Observed in SARS-CoV-2 Genomes Sampled From Successive Epochs Delimited by Major Public Health Events in Ontario, Canada: Genomic Surveillance Study. <i>JMIR Bioinformatics and Biotechnology</i> , 2022, 3, e42243.	0.4	0
576	Swimming competitions in the era of COVID-19: Lessons from successfully hosting the International Swimming League. <i>Physiology International</i> , 2022, , .	0.8	0
578	Identification of Genomic Variants of SARS-CoV-2 Using Nanopore Sequencing. <i>Medicina (Lithuania)</i> , 2022, 58, 1841.	0.8	2
579	Risk of SARS-CoV-2 reinfection: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2022, 12, .	1.6	18
580	Time to death and its predictors among adult patients with COVID-19: A retrospective cohort study in Ethiopia. , 0, 2, .		2
581	Genomic evidence of SARS-CoV-2 reinfection cases in southern Brazil. <i>Archives of Virology</i> , 2023, 168, .	0.9	0
582	Rapid System to Detect Variants of SARS-CoV-2 in Nasopharyngeal Swabs. <i>Viruses</i> , 2023, 15, 353.	1.5	0
585	Validation of a SARS-CoV-2 Surrogate Virus Neutralization Test in Recovered and Vaccinated Healthcare Workers. <i>Viruses</i> , 2023, 15, 426.	1.5	3
586	Evaluation of possible COVID-19 reinfection in children: A multicenter clinical study. <i>Archives De Pediatrie</i> , 2023, 30, 187-191.	0.4	2
587	SARS-CoV-2 multi-antigen protein microarray for detailed characterization of antibody responses in COVID-19 patients. <i>PLoS ONE</i> , 2023, 18, e0276829.	1.1	4
588	Epitope Coverage of Anti-SARS-CoV-2 Nucleocapsid IgA and IgG Antibodies Correlates with Protection against Re-Infection by New Variants in Subsequent Waves of the COVID-19 Pandemic. <i>Viruses</i> , 2023, 15, 584.	1.5	0
590	Reinfection of COVID-19 among doctors at a tertiary care centre in Northern India: A report from a resource-limited setting. <i>Lung India</i> , 2023, 40, 123.	0.3	1
591	Timely Pandemic Countermeasures Reduce both Health Damage and Economic Loss: Generality of the Exact Solution. <i>Journal of the Physical Society of Japan</i> , 2023, 92, .	0.7	0
592	Longitudinal analysis of SARS-CoV-2 reinfection reveals distinct kinetics and emergence of cross-neutralizing antibodies to variants of concern. <i>Frontiers in Microbiology</i> , 0, 14, .	1.5	0

#	ARTICLE	IF	CITATIONS
593	Real-time updating of dynamic social networks for COVID-19 vaccination strategies. Journal of Ambient Intelligence and Humanized Computing, 0, , .	3.3	4
595	Analysis of SARS-CoV-2 variants from patient specimens in Nevada from October 2020 to August 2021. Infection, Genetics and Evolution, 2023, 111, 105434.	1.0	1
596	Vaccination strategies in structured populations under partial immunity and reinfection. Journal of Physics A: Mathematical and Theoretical, 2023, 56, 204003.	0.7	4
627	COVID-19 therapy directed against pathogenic mechanisms of severe acute respiratory syndrome coronavirus 2. , 2024, , 2697-2726.		0